INSULIN RESISTANCE AS A CENTRAL MECHANISM IN METABOLIC SYNDROME: PATHOPHYSIOLOGY, CLINICAL IMPLICATIONS, AND THERAPEUTIC STRATEGIES

Ziyadullayev Akmal Xusniddin o'g'li
Residents of the clinical residency of the endocrinology department of the Samarkand State Medical University
Abdujabborov Umidjon Yunusovich
Residents of the clinical residency of the endocrinology department of the Samarkand State Medical University
Negmatova Gulzoda Shuhratovna
Department of endocrinology, Samarkand State Medical University

Annotation: *Metabolic syndrome is a multifactorial disorder characterized by a combination of central obesity, dyslipidemia, hypertension, and impaired glucose metabolism, all of which markedly increase the risk of type 2 diabetes mellitus and cardiovascular disease. Insulin resistance plays a pivotal role in the pathogenesis of metabolic syndrome by disrupting normal glucose and lipid homeostasis and promoting chronic low-grade inflammation and endothelial dysfunction. This study aims to evaluate insulin resistance as the central mechanism underlying metabolic syndrome, to describe its pathophysiological basis, and to assess its clinical implications. A comprehensive review of clinical and experimental studies was conducted, focusing on diagnostic markers of insulin resistance, associated metabolic abnormalities, and current therapeutic strategies. The findings indicate a strong association between insulin resistance and all major components of metabolic syndrome, including visceral obesity, dyslipidemia, and hypertension. Lifestyle interventions such as dietary modification, weight reduction, and increased physical activity were shown to significantly improve insulin sensitivity, while pharmacological therapies further reduced metabolic and cardiovascular risk in high-risk individuals. In conclusion, targeting insulin resistance is essential for the effective prevention and management of metabolic syndrome and its long-term complications.*

Keywords*: Insulin resistance, metabolic syndrome, pathophysiology, cardiovascular risk, type 2 diabetes mellitus, therapeutic strategies.*

Introduction

Metabolic syndrome is a complex cluster of interrelated metabolic abnormalities, including central obesity, dyslipidemia, hypertension, and impaired glucose metabolism, which together significantly increase the risk of type 2 diabetes mellitus and cardiovascular disease. Among these components, insulin resistance is widely recognized as the central pathophysiological mechanism driving the development and progression of metabolic syndrome. Insulin resistance is characterized by a reduced biological response of peripheral tissues, particularly skeletal muscle, adipose tissue, and the liver, to normal or elevated levels of insulin. This condition leads to compensatory hyperinsulinemia, altered glucose and lipid metabolism, chronic low-grade inflammation, and endothelial dysfunction. Understanding the role of insulin resistance is crucial for identifying high-risk individuals, improving diagnostic strategies, and developing effective preventive and therapeutic approaches.

Purpose: The aim of this study is to evaluate insulin resistance as the key underlying mechanism of metabolic syndrome, to analyze its pathophysiological pathways, and to assess its clinical consequences. Additionally, the study seeks to review current therapeutic strategies targeting insulin resistance and to determine their effectiveness in preventing metabolic and cardiovascular complications associated with metabolic syndrome.

Materials and Methods

This work is based on a comprehensive review of clinical and experimental studies published in peer-reviewed medical journals. Data were collected from studies involving patients diagnosed with metabolic syndrome according to internationally accepted criteria. The analysis included investigations of insulin sensitivity assessed by fasting insulin levels, the homeostasis model assessment of insulin resistance (HOMA-IR), oral glucose tolerance tests, and euglycemic–hyperinsulinemic clamp studies. Relevant data on lipid profiles, blood pressure, inflammatory markers, and anthropometric measurements were also examined. In addition, information on pharmacological and non-pharmacological interventions aimed at improving insulin sensitivity was systematically reviewed and compared.

Results

The reviewed studies consistently demonstrated a strong association between insulin resistance and all major components of metabolic syndrome. Individuals with elevated insulin resistance showed significantly higher levels of fasting glucose, triglycerides, and low-density lipoprotein cholesterol, along with reduced high-density lipoprotein cholesterol levels. Insulin resistance was also closely linked to visceral

adiposity, increased inflammatory cytokines, and endothelial dysfunction. Therapeutic interventions focusing on weight reduction, increased physical activity, and dietary modification resulted in marked improvements in insulin sensitivity and metabolic parameters. Pharmacological agents such as metformin, thiazolidinediones, and newer antidiabetic drugs were shown to reduce insulin resistance and lower the risk of progression to type 2 diabetes mellitus.

Discussion

The findings highlight insulin resistance as a unifying mechanism connecting metabolic, inflammatory, and vascular abnormalities in metabolic syndrome. Excess adipose tissue, particularly visceral fat, plays a key role in the development of insulin resistance through the release of free fatty acids and pro-inflammatory adipokines. These factors impair insulin signaling pathways and contribute to systemic metabolic dysfunction. Clinically, insulin resistance not only predisposes individuals to diabetes but also accelerates atherosclerosis and increases cardiovascular risk. Addressing insulin resistance through lifestyle modification remains the cornerstone of management, while pharmacological therapy should be considered in high-risk patients or when lifestyle interventions alone are insufficient. Early identification and intervention are essential to prevent long-term complications.

Conclusion

Insulin resistance is the central pathogenic mechanism underlying metabolic syndrome and its associated complications. A comprehensive approach that includes early diagnosis, lifestyle modification, and targeted pharmacological therapy is essential for effective management. Improving insulin sensitivity can significantly reduce the incidence of type 2 diabetes mellitus and cardiovascular disease, thereby enhancing long-term health outcomes in individuals with metabolic syndrome.

References:

1. Uskov A. et al. Modern methods of therapeutic fasting as a way to overcome the pharmacoresistance of mental pathology //Science and innovation. – 2023. – T. 2. – №. D12. – C. 179-185.

2. Abdukodirova S., . SPECIFIC CHARACTERISTICS AND TREATMENT OF ACUTE OBSTRUCTIVE BRONCHITIS IN CHILDREN OF EARLY AGE //Science and innovation. – 2023. – T. 2. – №. D11. – C. 5-8.

3. Tahirova J. et al. Insomnia problem causes of sleep disorder, help measures at home //Science and innovation. – 2022. – T. 1. – №. D8. – C. 521-525.

4. Sultanov S. et al. Long-term salbi effects of the covid-19 pandemic on the health of existing residents of alcohol addiction //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 430-438.

5. Madaminov M., . Breast cancer detection methods, symptoms, causes, treatment //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 530-535.

6. Шерназаров Самандар, Курбаниязова ВЕ, Виктория Саркисова Владимировна.(2023). Клиническое значение микробиоты кишечника у новорожденных с геморрагической болезнью. IQRO JURNALI, 2 (2), 867-877 [Электронный ресурс].

7. Tahirova J., . Symptoms of hymoritis, treatment, methods of folk medicine, prevention //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 983-990.

8. Jalalova D. et al. СОЧЕТАННАЯ СТОМАТОЛОГИЧЕСКАЯ И ГЛАЗНАЯ ПАТОЛОГИЯ //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 91-100.

9. Tohirova J. D. Jalalova TYPES OF HEMORRHAGIC DISEASES //CHANGES IN NEWBOENS, THEIR EARLY DIAGNOSIS.-2022.

10. Tahirova J. et al. Neurose causes and mechanisms of development, symptoms, treatment, prevention //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 515-520.

11. Kiyomov I., . IMPROVING SURGICAL TREATMENT METHODS FOR PATIENTS WITH NASAL PATHOLOGY //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 226-231.

12. Sarkisova V. et al. CYTOKINE PROFILE IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS (WEGENER'S) //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 336-343.

13. Sarkisova V., Lapasova Z., O. Rakhmanov INFLAMMATORY DISEASES OF THE PELVIC WOMEN ORGANS. – 2023.

14. Jalalova D., Raxmonov X., . РОЛЬ С–РЕАКТИВНОГО БЕЛКА В ПАТОГЕНЕЗЕ СОСУДИСТЫХ ЗАБОЛЕВАНИЙ ОРГАНА ЗРЕНИЯ У БОЛЬНЫХ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 114-121.

15. Malakhov A. et al. Modern views on the treatment and rehabilitation of patients with dementia //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 322-329.

16. Jalalova D., Raxmonov X., . ЗНАЧЕНИЕ ДИСФУНКЦИИ ЭНДОТЕЛИЯ В РАЗВИТИЕ РЕТИНОПАТИИ У БОЛЬНЫХ АГ И ПУТИ ЕГО КОРРЕКЦИИ //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 101-113.

17. Madaminov M., .Acute tonsillitis (angina) causes, complications, diagnosis, treatment, prevention //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 771-779.

18. F. The problem of insomnia causes of sleep disorder, remedies at home //Science and innovation. – 2023. – Т. 2. – №. D1. – С. 79-84.